JP2014532038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532038A5 JP2014532038A5 JP2014529893A JP2014529893A JP2014532038A5 JP 2014532038 A5 JP2014532038 A5 JP 2014532038A5 JP 2014529893 A JP2014529893 A JP 2014529893A JP 2014529893 A JP2014529893 A JP 2014529893A JP 2014532038 A5 JP2014532038 A5 JP 2014532038A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- methoxy
- tert
- ethyl
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 45
- -1 1-tert-butyl - butyl Chemical group 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 108020001756 ligand binding domains Proteins 0.000 claims description 17
- 239000000654 additive Substances 0.000 claims description 14
- LZWZPGLVHLSWQX-XMMPIXPASA-N n'-(3,5-dimethylbenzoyl)-n'-[(3r)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide Chemical compound C=1C(C)=CC(C)=CC=1C(=O)N([C@H](CCC)C(C)(C)C)NC(=O)C1=CC=CC(OC)=C1CC LZWZPGLVHLSWQX-XMMPIXPASA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 6
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 108010057988 ecdysone receptor Proteins 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000749 insecticidal effect Effects 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- LZWZPGLVHLSWQX-DEOSSOPVSA-N n'-(3,5-dimethylbenzoyl)-n'-[(3s)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide Chemical compound C=1C(C)=CC(C)=CC=1C(=O)N([C@@H](CCC)C(C)(C)C)NC(=O)C1=CC=CC(OC)=C1CC LZWZPGLVHLSWQX-DEOSSOPVSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532368P | 2011-09-08 | 2011-09-08 | |
| US61/532,368 | 2011-09-08 | ||
| PCT/US2012/054141 WO2013036758A1 (en) | 2011-09-08 | 2012-09-07 | Crystalline diacylhydrazine and the use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015175584A Division JP6463237B2 (ja) | 2011-09-08 | 2015-09-07 | 結晶性ジアシルヒドラジンおよびその使用 |
| JP2018073426A Division JP6522826B2 (ja) | 2011-09-08 | 2018-04-05 | 結晶性ジアシルヒドラジンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532038A JP2014532038A (ja) | 2014-12-04 |
| JP2014532038A5 true JP2014532038A5 (cg-RX-API-DMAC10.html) | 2015-11-05 |
| JP6347745B2 JP6347745B2 (ja) | 2018-06-27 |
Family
ID=47832584
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529893A Expired - Fee Related JP6347745B2 (ja) | 2011-09-08 | 2012-09-07 | 結晶性ジアシルヒドラジンおよびその使用 |
| JP2015175584A Expired - Fee Related JP6463237B2 (ja) | 2011-09-08 | 2015-09-07 | 結晶性ジアシルヒドラジンおよびその使用 |
| JP2018073426A Expired - Fee Related JP6522826B2 (ja) | 2011-09-08 | 2018-04-05 | 結晶性ジアシルヒドラジンおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015175584A Expired - Fee Related JP6463237B2 (ja) | 2011-09-08 | 2015-09-07 | 結晶性ジアシルヒドラジンおよびその使用 |
| JP2018073426A Expired - Fee Related JP6522826B2 (ja) | 2011-09-08 | 2018-04-05 | 結晶性ジアシルヒドラジンおよびその使用 |
Country Status (18)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX369690B (es) * | 2011-09-08 | 2019-11-19 | Intrexon Corp | Diacilhidrazina cristalina y sus usos. |
| DK3182962T3 (da) * | 2014-08-22 | 2023-09-18 | Biocryst Pharm Inc | Compositions and uses of amidine derivatives |
| US20180200209A1 (en) * | 2015-07-10 | 2018-07-19 | Millendo Therapeutics, Inc. | Enhanced bioavailability of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl)methyl)urea hydrochloride |
| WO2017094019A1 (en) * | 2015-12-02 | 2017-06-08 | Indian Institute Of Science | A method for rapid detection of a single bacterium |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN108078969B (zh) * | 2017-12-25 | 2020-06-30 | 临沂大学 | 萘酰肼类化合物在制备抗微生物药物中的用途 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2707012B2 (ja) * | 1991-12-06 | 1998-01-28 | キッセイ薬品工業株式会社 | Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法 |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| AU2002306550B2 (en) | 2001-02-20 | 2007-10-25 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| CA2438119C (en) | 2001-02-20 | 2014-12-16 | Rheogene Holdings, Inc. | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| EP1490686A2 (en) | 2001-09-26 | 2004-12-29 | RheoGene Holdings Inc. | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| JP2005532781A (ja) | 2001-09-26 | 2005-11-04 | レオジーン・ホールディングス，インコーポレーテッド | ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用 |
| EP1480988A4 (en) | 2002-03-01 | 2006-03-29 | Univ Columbia | REAGENTS FOR ASYMMETRIC ALLYLATION, ALDOL AND TANDEM ALDOL AND ALLYLATION REACTIONS |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7456315B2 (en) * | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| CA3050564A1 (en) | 2003-08-29 | 2005-03-10 | Dyax Corp. | Poly-pegylated protease inhibitors |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US20070213275A1 (en) | 2006-03-10 | 2007-09-13 | Dyax Corp. | Formulations for ecallantide |
| MX363066B (es) | 2007-05-29 | 2019-03-07 | Intrexon Corp | Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona. |
| US20090098055A1 (en) * | 2007-08-23 | 2009-04-16 | Intrexon Corporation | Methods and Compositions for Diagnosing Disease |
| US20090136465A1 (en) * | 2007-09-28 | 2009-05-28 | Intrexon Corporation | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof |
| JP2010539993A (ja) | 2007-10-08 | 2010-12-24 | イントレキソン コーポレーション | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| MX340972B (es) * | 2008-10-08 | 2016-08-02 | Intrexon Corp | Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas. |
| MX369690B (es) * | 2011-09-08 | 2019-11-19 | Intrexon Corp | Diacilhidrazina cristalina y sus usos. |
-
2012
- 2012-09-07 MX MX2017005654A patent/MX369690B/es unknown
- 2012-09-07 KR KR1020147009225A patent/KR102033138B1/ko not_active Expired - Fee Related
- 2012-09-07 PH PH1/2021/551061A patent/PH12021551061A1/en unknown
- 2012-09-07 KR KR1020217015216A patent/KR20210069112A/ko not_active Withdrawn
- 2012-09-07 EP EP12829775.1A patent/EP2751072B1/en active Active
- 2012-09-07 EP EP18190199.2A patent/EP3461810B1/en active Active
- 2012-09-07 CN CN201280054692.7A patent/CN103917519B/zh not_active Expired - Fee Related
- 2012-09-07 WO PCT/US2012/054141 patent/WO2013036758A1/en not_active Ceased
- 2012-09-07 TW TW101132750A patent/TWI586640B/zh not_active IP Right Cessation
- 2012-09-07 SG SG10201705596TA patent/SG10201705596TA/en unknown
- 2012-09-07 CA CA2848222A patent/CA2848222C/en active Active
- 2012-09-07 RU RU2014111288A patent/RU2629113C2/ru active
- 2012-09-07 PH PH1/2020/551916A patent/PH12020551916A1/en unknown
- 2012-09-07 CA CA3061802A patent/CA3061802C/en active Active
- 2012-09-07 JP JP2014529893A patent/JP6347745B2/ja not_active Expired - Fee Related
- 2012-09-07 KR KR1020197029814A patent/KR102256613B1/ko not_active Expired - Fee Related
- 2012-09-07 SG SG11201400350VA patent/SG11201400350VA/en unknown
- 2012-09-07 BR BR112014005509-2A patent/BR112014005509B1/pt not_active IP Right Cessation
- 2012-09-07 CN CN202011607753.0A patent/CN112778157A/zh not_active Withdrawn
- 2012-09-07 AU AU2013201096A patent/AU2013201096B2/en not_active Ceased
- 2012-09-07 MX MX2014002629A patent/MX350158B/es active IP Right Grant
- 2012-09-07 PH PH1/2014/500528A patent/PH12014500528A1/en unknown
- 2012-09-07 DK DK12829775.1T patent/DK2751072T3/en active
- 2012-09-07 ES ES12829775T patent/ES2710212T3/es active Active
- 2012-09-07 CN CN201610518794.XA patent/CN106187812A/zh active Pending
- 2012-09-07 US US13/606,444 patent/US8946294B2/en active Active
-
2014
- 2014-03-04 IL IL231310A patent/IL231310B/en active IP Right Grant
- 2014-03-05 MX MX2019009224A patent/MX2019009224A/es unknown
- 2014-03-19 ZA ZA2014/02010A patent/ZA201402010B/en unknown
- 2014-10-21 US US14/519,408 patent/US9604913B2/en not_active Expired - Fee Related
-
2015
- 2015-06-03 PH PH12015501266A patent/PH12015501266B1/en unknown
- 2015-09-07 JP JP2015175584A patent/JP6463237B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-04 US US15/398,236 patent/US10501405B2/en active Active
-
2018
- 2018-04-05 JP JP2018073426A patent/JP6522826B2/ja not_active Expired - Fee Related
-
2019
- 2019-10-28 US US16/665,938 patent/US20200048188A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240122925A1 (en) | Shp2 phosphatase inhibitors and methods of making and using the same | |
| AU2019356565B2 (en) | Prodrug modulators of the integrated stress pathway | |
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| EP3704096B1 (en) | Modulators of the integrated stress pathway | |
| JP2019525962A (ja) | ケモカイン受容体調節剤及びそれの使用 | |
| JP2019514884A (ja) | Ｅｚｈ２インヒビターおよびそれらの使用 | |
| JP2011527683A5 (cg-RX-API-DMAC10.html) | ||
| JP2020517611A5 (cg-RX-API-DMAC10.html) | ||
| AU2018360847A1 (en) | Modulators of the integrated stress pathway | |
| JP7248261B2 (ja) | 癌を処置するための医薬組成物 | |
| WO2023086962A1 (en) | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof | |
| JP2015508092A5 (cg-RX-API-DMAC10.html) | ||
| JP2013513588A5 (cg-RX-API-DMAC10.html) | ||
| JP2021105003A (ja) | 多形体及びキナゾリニル誘導体の調製プロセス | |
| CN105324375A (zh) | 盐酸尼洛替尼的多晶型形式 | |
| JP2009541493A5 (cg-RX-API-DMAC10.html) | ||
| WO2019025588A1 (en) | METHODS OF TREATING ALTERATIONS IN BEHAVIOR | |
| JP2016508135A5 (cg-RX-API-DMAC10.html) | ||
| JP2016512198A5 (cg-RX-API-DMAC10.html) | ||
| RU2014111288A (ru) | Кристаллический диацилгидразин и его применение | |
| JP2020502077A5 (cg-RX-API-DMAC10.html) | ||
| CN103298777B (zh) | 苯基酮羧酸盐化合物和其药学用途 | |
| WO2014052659A1 (en) | Crystalline forms of neurotrophin mimetic compounds and their salts | |
| AU2021227281A1 (en) | Potassium salt of 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid | |
| JP2009523711A5 (cg-RX-API-DMAC10.html) |